METASTATIC CASTRATION-RESISTANT PROSTATE ADENOCARCINOMA

The initial treatments for localized prostate cancer, with a curative intent, are radical prostatectomy or radiation. However, these options cannot be applied to cases with locally advanced or metastatic disease. Objective: To characterize patients with metastatic prostate adenocarcinoma resistant to castration, treated with the chemotherapy regimen Docetaxel plus prednisone at the National Institute of Oncology and Radiobiology in the period 2008-2015.Material and Method:A quantitative, descriptive, retrospective non-experimental study was conducted to determine the characteristics of patients with metastatic castration-resistant prostate adenocarcinoma treated with the Docetaxel plus prednisone chemotherapy regimen.Results:A total of 40 patients were studied of which 50% were 60 and 69 years old and 30% 70 and 79 years old, with the mean age of presentation of CRPC being 67.3 years. 100% of the patients were in stage IV because of distant metastasis.